Related Experiment Videos

Changes of copper level and cytochrome c oxidase activity in the macular mouse with age

Y Meguro1, H Kodama, T Abe

  • 1Department of Pediatrics, Teikyo University, School of Medicine, Tokyo, Japan.

Insights

Parenteral copper administration in infancy may benefit Menkes disease patients. Macular mice showed improved cytochrome c oxidase (CCO) activity with age, linked to increased brain copper levels.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Genetics

Background:

  • Menkes disease is a genetic disorder causing neurological degeneration due to copper deficiency.
  • The macular mouse serves as an animal model for studying Menkes disease.
  • Cuproenzymes, like cytochrome c oxidase (CCO), are vital for brain function and are affected by copper levels.

Purpose of the Study:

  • To investigate age-related changes in brain copper concentration and CCO activity in macular mice.
  • To assess the impact of early copper supplementation on neurological recovery in the macular mouse model.
  • To establish a correlation between brain copper levels and CCO activity in the context of Menkes disease.

Main Methods:

  • Macular mice received a single injection of cupric on postnatal day 7.
  • Brain copper concentration was measured at various time points.
  • Cytochrome c oxidase (CCO) activity in the brain was assessed.
  • Age-matched control mice were used for comparison.

Main Results:

  • Macular mice consistently showed approximately 40% lower brain copper concentration than controls.
  • Both macular and control mice exhibited a gradual increase in brain copper with age.
  • CCO activity was significantly lower in macular mice at 8 days but normalized by 180 days.
  • The recovery of CCO activity correlated with increasing brain copper levels.

Conclusions:

  • Increased brain copper concentration with age contributes to improved CCO activity in macular mice.
  • Early parenteral copper administration is recommended for Menkes disease patients, particularly during infancy.
  • The macular mouse model demonstrates potential for evaluating therapeutic strategies for Menkes disease.

Related Concept Videos